8th August 2022 | Pharma Updates

Latest pharmaceutical industry news and updates

Cipla investing heavily in digitisation and emerging markets

Cipla is betting big on digitisation and emerging segments like biosimilars and mRNA-assisted medications to drive its next phase of growth and also optimistic about capitalizing on value opportunities in the complex generics market in the United States.

IPC issues safety alert for immunosuppressive drug tacrolimus

Indian Pharmacopoeia Commission (IPC), which serves as the National Coordination Centre (NCC) for the Pharmacovigilance Programme of India has issued a drug safety alert revealing that the immunosuppressive medication tacrolimus is linked to gingival hypertrophy.

Gifts and Freebies for Prescriptions: Pharma Bribery of Doctors topic in Parliament

The issue of pharmaceutical companies engaging in unfair and unethical practices to promote their medicines by sponsoring trips and providing gifts to doctors recently came up in Lok Sabha sessions.

Lumakras plus immunotherapy for lung cancer needs more research, as per Amgen

According to the company, a small study of Amgen Inc’s Lumakras drug combined with immunotherapy found it helped 29 percent of advanced lung cancer patients, but liver toxicity was high and more research is needed.

Pharma companies enlisted by Govtto encourage employee participation in "Har Ghar Tiranga"

To promote the ‘Har Ghar Tiranga’ programme, the Department of Pharmaceuticals has written to the Indian Drug Manufacturers Association and other stakeholders.

AiMeD requests creation of separate Dept for medical devices from Prime Minister

Association of Indian Medical Device Industry (AiMeD) has urged Prime Minister Narendra Modi to either rename the Department of Pharmaceuticals to the Department of Pharmaceuticals & Medical Devices or create a separate Department of Medical Devices.

US FDA approved AstraZeneca's new Calquence tablet formulation for all current indications

All current indications for Calquence, including adult patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, and patients with relapsed or refractory mantle cell lymphoma, have been given accelerated approval in the US by AstraZeneca based on overall response rate.

PharmaState.academy offers easy access to training & up-skilling programs created by experts from Pharma Industry.

Welcome to PharmaState Academy

Install
×
Start chat
1
Need Help?
PharmaState Academy
Hello, how can we help you?